Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ASC47 Injection in Healthy and Obese Subjects
NCT06427590Phase 1Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Jul 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASC47 in obesity (4 cohorts), sponsored by Ascletis Pharma Inc. Primary endpoints: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 up to 57 days, ECG QT Interval up to 57 days and 2 more. Started Jul 2024; status: completed.
02
Drugs
ASC47
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06427590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06427590.